Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
NASDAQ: SHPH · Real-Time Price · USD
1.800
+0.480 (36.36%)
At close: Oct 29, 2024, 4:00 PM
1.700
-0.100 (-5.56%)
After-hours: Oct 29, 2024, 7:59 PM EDT

Company Description

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers.

It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .

The company is based in Gaithersburg, Maryland.

Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings logo
Country United States
Founded 2012
IPO Date Aug 31, 2022
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 8
CEO Anatoly Dritschilo

Contact Details

Address:
401 Professional Drive, Suite 260
Gaithersburg, Maryland 20879
United States
Phone (240) 403-4212
Website shuttlepharma.com

Stock Details

Ticker Symbol SHPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $8.13
CIK Code 0001757499
CUSIP Number 825693203
ISIN Number US8256932034
SIC Code 2834

Key Executives

Name Position
Dr. Anatoly Dritschilo M.D. Co-Founder, Chief Executive Officer and Chairman of the Board
Peter Dale Dritschilo M.B.A., M.D. President and Chief Operating Officer
Dr. Milton Brown CSC, M.D., Ph.D. Co-Founder and Director
Dr. Tyvin A. Rich M.D. Chief Clinical Officer and Chief Medical Officer
Dr. Mira Jung Ph.D. Co-Founder and Chief Scientific Officer for Biology
Timothy J. Lorber CPA Chief Financial Officer
Gene Jung Esq. General Counsel

Latest SEC Filings

Date Type Title
Oct 29, 2024 8-K Current Report
Oct 28, 2024 8-K Current Report
Oct 28, 2024 8-K Current Report
Oct 25, 2024 8-K Current Report
Oct 25, 2024 D Notice of Exempt Offering of Securities
Oct 18, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Oct 17, 2024 8-K Current Report
Sep 20, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Sep 16, 2024 424B3 Prospectus
Sep 13, 2024 8-K Current Report